Research programme: Proto oncogene proteins c-akt inhibitors - ProlX
Alternative Names: Protein kinase B inhibitors - ProlX; PX-316Latest Information Update: 04 Nov 2017
At a glance
- Originator ProlX Pharmaceuticals
- Class Sugar alcohols
- Mechanism of Action Proto-oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Brain cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Brain-cancer in USA
- 31 Oct 2006 ProlX Pharmaceuticals has been acquired by Biomira
- 02 Aug 2006 This programme is still in active development